Skip to content

Frontiers in Pharmacology

ISSN 1663-9812

169 papers in the library · 6,125 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex

Frontiers in Pharmacology October 16, 2026 Qingmei Li, Shuming Liu, Huiling Chen et al.

Objective The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC). Methods Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK...

Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable prediction

Frontiers in Pharmacology September 30, 2026 Kacper Żełabowski, Tomasz Wieczorek, Adam Hamed

Stroboscopic light stimulation (SLS) and psilocybin each induce altered states whose phenomenology and neurophysiology partly overlap, including posterior alpha-band changes and visual imagery. The two states engage the alpha band through different operations - pharmacological suppression under psilocybin and frequency-selective visual drive under SLS. We formalize their possible interaction...

Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice

Frontiers in Pharmacology September 22, 2026 David Ernst Hogg, Jennifer Romanos, Jamie Albiez et al.

There is considerable interest in the concept that psychedelic compounds might facilitate reorganization of emotional processing with therapeutic benefit; in particular, amelioration of excessive focus on past, current and potential-future aversive events, a dominant emotional-cognitive state in stress-related affective disorders. Translational animal models can advance understanding of...

Evaluation of the therapeutic efficacy of the dextromethorphan–bupropion combination and its mediating pathways in a mouse model of major depressive disorder

Frontiers in Pharmacology August 19, 2026 İlay Buran Kavuran, Ebru Önalan, Zeliha İrem Türk et al.

Background Major depressive disorder (MDD) is associated with multiple pathophysiological mechanisms, including dysregulation of monoaminergic systems, excessive glutamatergic activity, reduced neurotrophic support, inflammation, and oxidative stress. The combination of dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a...

THC and CBD differentially modulated gut microbiota in the Poly I:C rat model of schizophrenia

Frontiers in Pharmacology August 10, 2026 N. Miguel-Ramiro, N. Lamanna-Rama, M. Casquero-Veiga et al.

Background Disruptions in the gut-brain-microbiota axis are increasingly linked to psychiatric disorders. While cannabinoids possess immunomodulatory and neuroprotective properties, their impact on the microbial architecture during critical neurodevelopmental periods remains poorly understood. This exploratory study investigated whether adolescent treatment with delta-9-tetrahydrocannabinol...

Efficacy and safety of perioperative esketamine for postoperative depressive symptoms in breast cancer patients: a meta-analysis

Frontiers in Pharmacology July 8, 2026 Ruoyi Ji, Xinyuan Shi, X Q Liu et al.

Background: Postoperative depressive symptoms may impair recovery and quality of life in patients undergoing breast cancer surgery. Esketamine has shown potential antidepressant and analgesic effects in the perioperative setting. This meta-analysis evaluated the efficacy and safety of perioperative esketamine for postoperative depressive symptoms in patients undergoing breast cancer surgery....

Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats

Frontiers in Pharmacology June 29, 2026 Laura Gálvez-melero, Sandra Ledesma-Corvi, C. Bis-Humbert et al.

There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression. In this context, combination therapies, particularly cannabidiol with temozolomide exhibited additive or synergistic anti-tumor effects, capable...

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

Frontiers in Pharmacology June 3, 2026 Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung

Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...

DOI: 10.3389/fphar.2026.1840956 (opens in new tab) Traumatic brain injury Mood Therapeutic effect Depression economics +6

Amanita muscaria in the evolving novel psychoactive substances landscape - toxicological risks and clinical implications: a narrative review

Frontiers in Pharmacology May 26, 2026 Michal Ordak

The rapid evolution of the novel psychoactive substances market has blurred the boundaries between synthetic “designer drugs” and other emerging psychoactive products distributed outside traditional regulatory frameworks. Recently, increasing recreational and self-therapeutic interest in Amanita muscaria has led to its growing presence within the broader landscape of substances used in patterns...

DOI: 10.3389/fphar.2026.1838212 (opens in new tab) Cannabis Context archaeology Narrative review Recreational drug +6

Interplay between the HPA axis and inflammation as mechanisms therapeutic targets of Cannabis sativa in depression

Frontiers in Pharmacology May 19, 2026 Fernanda Pilatti, Marieli Philippsen, A. G. Bertollo et al.

Major Depressive Disorder (MDD) is a highly prevalent and disabling psychiatric disorder, representing a major global health burden across all age groups. Increasing evidence indicates that its pathophysiology involves a complex interplay between chronic stress, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, immune activation, and neuroinflammation. Persistent HPA axis...

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application

Frontiers in Pharmacology March 16, 2026 Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino

psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...

DOI: 10.3389/fphar.2026.1816812 (opens in new tab) Addiction Neurotoxicity Mechanism biology Recreational use +7

Exploring Colombian medicinal flora used in indigenous and campesino health systems for neuropsychiatric disorders and neuropharmacological potential: an ethnopharmacological review

Frontiers in Pharmacology March 11, 2026 Katrin Brache, Mauricio Diazgranados

Neuropsychiatric disorders affect nearly one billion people worldwide, yet many existing psychopharmacological treatments are limited by adverse effects, drug interactions, and variable efficacy. Ethnopharmacological knowledge embedded in Indigenous health systems offers important perspectives for understanding mental and neurological distress and for informing future research on central...

DOI: 10.3389/fphar.2026.1729887 (opens in new tab) Ayahuasca Indigenous Ethnobotany Medicinal plants +13

Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial

Frontiers in Pharmacology March 4, 2026 Mi Zhou, Y M Qi, Fan Zhou et al.

Objective To evaluate outcomes of different doses of esketamine in postoperative patient-controlled intravenous analgesia (PCIA) combined with preoperative intercostal nerve block (ICNB) analgesia protocol for acute postoperative pain (APP) relief in patients undergoing thoracoscopic lobectomy. Materials and methods A total of 360 patients scheduled for thoracoscopic lobectomy at Xuzhou Central...

DOI: 10.3389/fphar.2026.1746121 (opens in new tab) Ketamine Randomized controlled trial Sufentanil Incidence geometry +11

Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables.

Frontiers in Pharmacology 2026 Michaela Krivosova, Matteo Marcatili, Gessica Guerrera et al.

Esketamine, the S-enantiomer of ketamine, is a rapid-acting antidepressant approved for treatment-resistant depression (TRD) when used in combination with an oral antidepressant. Identifying reliable clinical or genetic predictors of treatment response remains a critical unmet need. This study aimed to evaluate the impact of selected clinical and genetic variables on esketamine response in a...

Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in Pharmacology 2026 Yang Qu, Shujin Li, Li Tian et al.

This study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing. PubMed, Embase, the Cochrane Library, the Mainland China Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI) and Wanfang databases...

The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats.

Frontiers in Pharmacology 2026 Patricio Sáez-briones, Amanda Silva-Rodríguez, Michelle Morales-Vidal et al.

In humans, empathy is expressed through various prosocial behaviours between individuals that may be enhanced after intake of the synthetic entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") as the behavioural expression of the so-called entactogenic syndrome. Rodents may also exhibit empathy-like behaviours, such as social interaction and helping behaviour. In this regard, while...

DOI: 10.3389/fphar.2026.1779772 (opens in new tab) Full text (opens in new tab) Serotonin 3,4-methylenedioxymethamphetamine Helping behaviour Oxytocin

Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology.

Frontiers in Pharmacology 2026 Joseph Geraci, Erik Viirre, Bessi Qorri et al.

Classical serotonergic psychedelics (e.g., LSD, psilocybin, DMT) alter perception and neuroplasticity primarily via 5-HT2A receptor activation and downstream Ca2+-dependent signaling cascades. Here we propose a speculative yet falsifiable pharmacological hypothesis that these drug-induced biochemical cascades might interface with quantum-mechanical processes in the brain. We focus on nuclear...

Locomotor and discriminative stimulus effects of N-cyclohexyl butylone and N-cyclohexyl methylone.

Frontiers in Pharmacology 2026 Michael B. Gatch, Shuping Jia, Ritu A. Shetty et al.

N-Cyclohexyl butylone and N-cyclohexyl methylone are cathinones found on the street that produce morbidity and mortality, but are not yet legally controlled, and there has been little or no pharmacological testing of these compounds. Both compounds have a large moiety on the N-position that may alter their pharmacological effects. Locomotor stimulant effects of N-cyclohexyl butylone and...

5-HT2A receptor activation induces CB1-dependent presynaptic inhibitory long-term depression in the nucleus accumbens core.

Frontiers in Pharmacology 2026 Camila Estay-Olmos, Koyam Morales-Weil, Juan Ahumada et al.

The serotonin 2A receptor (5-HT2A) is a Gq/11-coupled receptor implicated in reward processing, neuropsychiatric disorders, and the actions of serotonergic psychedelics. Although 5-HT2A activation has been shown to engage endocannabinoid (eCB) signaling in several brain regions, its role in inhibitory synaptic plasticity within the nucleus accumbens (NAc) remains poorly understood. Here, we...

Ibogaine’s potential role in supporting reward system recovery across diagnostic boundaries

Frontiers in Pharmacology December 4, 2025 Maya Nicolas

This article proposes that ibogaine’s induction of GDNF, modulation of glutamate and dopamine signaling, and reopening of plasticity represent a unified mechanism capable of restoring reward system fidelity across disorders. This includes addiction, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and eating disorders, amongst others. These conditions are labelled as...

Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology December 1, 2025 Tiejia Jiang, Rui Zhao

As a therapy for postoperative analgesia, esketamine shows relatively favorable efficacy in pain control and is associated with a lower risk of postpartum depression. However, this result is unstable. Furthermore, esketamine may increase the risk of dizziness in pregnant women aged over 30 years. Since all the experiments in this study are conducted in China, there are certain regional...

DOI: 10.3389/fphar.2025.1708221 (opens in new tab) Ketamine Randomized controlled trial Anesthesia Pain control +4

Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines

Frontiers in Pharmacology November 20, 2025 Karolina E. Kolaczynska, Daniel Trachsel, Marius C. Hoener et al. 1 citation

Background 4-substituted 2,6-dimethoxyphenethylamines and the corresponding amphetamines (so-called pseudo [Ψ] derivatives) are a hitherto mostly unexplored group of psychedelics. Still, preliminary investigations indicate that these derivatives are promising and potent psychedelics in humans. In this study, we examined the monoamine receptor and transporter interaction properties of several...

DOI: 10.3389/fphar.2025.1703480 (opens in new tab) Receptor Cricetulus Structure–activity relationship Hek 293 cells +7

Integrated metabolomics and gut microbiota analysis to explore the potential mechanism of levo-tetrahydropalmatine against ketamine addiction

Frontiers in Pharmacology November 19, 2025 Yan Du, Qing Ma, Xingcui Gao et al.

Introduction Metabolic and gut microbiota (GM) disturbance play a significant role in the complex pathogenesis of substance dependence. Although levo-tetrahydropalmatine (l-THP) demonstrates therapeutic potential in drug addiction, the underlying mechanism remains elusive. Methods The efficacy of l-THP was assessed using a conditioned place preference (CPP) paradigm. In this research, we...

Esketamine versus fentanyl as adjuncts to hepatic hilar nerve block for ambulatory percutaneous liver tumor ablation focusing on respiratory safety: protocol for a randomized controlled trial

Frontiers in Pharmacology September 17, 2025 Xiao Wang, Lijuan Yan, Jiaying Cai et al. 1 citation

This trial aims to provide Level I evidence comparing the respiratory depression risk between esketamine-based and fentanyl-based analgesia during HHNB-guided liver ablation. Should esketamine prove to be demonstrably superior in terms of respiratory safety, HHNB-esketamine has the potential to be a viable treatment option.

DOI: 10.3389/fphar.2025.1644029 (opens in new tab) Ketamine Fentanyl Anesthesia Randomized controlled trial +6

Psychedelics and mental health: reimagining care through science, insight, and compassion.

Frontiers in Pharmacology September 3, 2025 Georgios Mikellides, Marios Kyriazis 3 citations

In recent years, psychiatry has witnessed a renaissance in the investigation of psychedelic compounds, a broad class of psychoactive substances that induce altered states of consciousness, often characterized by changes in perception, mood, and cognition, which were largely shelved following regulatory crackdowns in the 1970s. The renewed interest is driven by a mounting crisis in mental health...

DOI: 10.3389/fphar.2025.1649929 (opens in new tab) Full text (opens in new tab) Psychedelic therapy psychedelics Treatment Care Healing +11